Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

NCT00863798 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

682

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: Desvenlafaxine Succinate Sustained-Release 10mg
DRUG: Desvenlafaxine Succinate Sustained-Release 50 mg
DRUG: placebo

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Collaborators

[object Object]